Missolapola schreef op 16 oktober 2019 11:59:
HitGen teams up Galapagos to develop small molecule therapies
Oct. 16, 2019 5:55 AM ETGalapagos NV (GLPG)By: Mamta Mayani, SA News Editor
HitGen has entered into a drug discovery research collaboration with Galapagos NV (NASDAQ:GLPG) to identify potential small molecule leads against targets of interest to Galapagos NV.
In this collaboration, HitGen will apply its technology platform, based on DNA-encoded library design, synthesis and interrogation, to discover novel leads.
Under the terms of the agreement, HitGen will receive an undisclosed upfront payment and milestone payments.
GLPG shares are up 1% premarket.